Dss, inc. announces sale of celios® to impact biomedical, streamlining portfolio for strategic growth

Rochester, n.y., feb. 26, 2025 (globe newswire) -- dss, inc. (nyse american: dss), a multinational company focused on innovation-driven business models, today announced the sale of its celios® air purification asset to impact biomedical inc. (nyse american: ibo) in a strategic, all-equity transaction valued at approximately $1.15 million. this divestiture aligns with dss' ongoing strategy to optimize its portfolio and concentrate on core growth areas.
DSS Ratings Summary
DSS Quant Ranking